The importance of tau phosphorylation for neurodegenerative diseases

Frontiers in Neurology

Volumn 4 JUL, Issue , 2013, Pages

  Noble, Wendy ^a   Hanger, Diane P ^a   Miller, Christopher C J ^a   Lovestone, Simon ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; Extracellular; Function; Oligomers; Phosphorylation; Tau

Indexed keywords

ADENYLATE KINASE; AMPA RECEPTOR; CASPASE 3; CYCLIN DEPENDENT KINASE 5; GLYCOGEN SYNTHASE KINASE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; LITHIUM; MESSENGER RNA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHOSPHOPROTEIN PHOSPHATASE 2A; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE FYN; TAU PROTEIN; TIDEGLUSIB;

ALZHEIMER DISEASE; CARBOXY TERMINAL SEQUENCE; CONFORMATIONAL TRANSITION; DEGENERATIVE DISEASE; DENDRITIC CELL; DNA DAMAGE; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FRONTOTEMPORAL DEMENTIA; HUMAN; NERVE CELL PLASTICITY; NERVE DEGENERATION; NERVE FIBER TRANSPORT; NEUROFIBRILLARY TANGLE; NONHUMAN; OXIDATIVE STRESS; PROTEIN AGGREGATION; PROTEIN CLEAVAGE; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT;

EID: 84883524853     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2013.00083     Document Type: Review

References (165)

1. Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science (2005) 309:476-81. doi:10.1126/science.1113694
2. Berger Z, Roder H, Hanna A, Carlson A, Rangachari V, Yue M, et al. Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J Neurosci (2007) 27:3650-62. doi:10.1523/JNEUROSCI.0587-07.2007
3. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell (2010) 142:387-97. doi:10.1016/j.cell.2010.06.036
4. Rocher AB, Crimins JL, Amatrudo JM, Kinson MS, Todd-Brown MA, Lewis J, et al. Structural and functional changes in tau mutant mice neurons are not linked to the presence of NFTs. Exp Neurol (2010) 223:385-93. doi:10.1016/j.expneurol.2009.07.029
5. Togo T, Sahara N, Yen SH, Cookson N, Ishizawa T, Hutton M, et al. Argyrophilic grain disease is a sporadic 4-repeat tauopathy. J Neuropathol Exp Neurol (2002) 61:547-56.
6. Zhukareva V, Mann D, Pickering-Brown S, Uryu K, Shuck T, Shah K, et al. Sporadic Pick's disease: a tauopathy characterized by a spectrum of pathological tau isoforms in gray and white matter. Ann Neurol (2002) 51(6):730-9. doi:10.1002/ana.10222
7. Connell JW, Rodriguez-Martin T, Gibb GM, Kahn NM, Grierson AJ, Hanger DP, et al. Quantitative analysis of tau isoform transcripts in sporadic tauopathies. Brain Res Mol Brain Res (2005) 137:104-9. doi:10.1016/j.molbrainres.2005.02.014
8. Hanger DP, Anderton BH, Noble W. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med (2009) 15:112-9. doi:10.1016/j.molmed.2009.01.003
9. Noble W, Pooler AM, Hanger DP. Advances in tau-based drug discovery. Expert Opin Drug Discov (2011) 6:797-810. doi:10.1517/17460441.2011.586690
10. Hanger DP, Byers HL, Wray S, Leung KY, Saxton MJ, Seereeram A, et al. Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis. J Biol Chem (2007) 282:23645-54. doi:10.1074/jbc.M703269200
11. Sergeant N, Wattez A, Delacourte A. Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration: tau pathologies with exclusively "exon 10" isoforms. J Neurochem (1999) 72:1243-9. doi:10.1046/j.1471-4159.1999.0721243.x
12. Arai T, Ikeda K, Akiyama H, Nonaka T, Hasegawa M, Ishiguro K, et al. Identification of amino-terminally cleaved tau fragments that distinguish progressive supranuclear palsy from corticobasal degeneration. Ann Neurol (2004) 55:72-9. doi:10.1002/ana.10793
13. Wray S, Saxton M, Anderton BH, Hanger DP. Direct analysis of tau from PSP brain identifies new phosphorylation sites and a major fragment of N-terminally cleaved tau containing four microtubule-binding repeats. J Neurochem (2008) 105:2343-52. doi:10.1111/j.1471-4159.2008.05321.x
14. Hanger DP, Brion JP, Gallo JM, Cairns NJ, Luthert PJ, Anderton BH. Tau in Alzheimer's disease and Down's syndrome is insoluble and abnormally phosphorylated. Biochem J (1991) 275(Pt 1):99-104.
15. Morishima-Kawashima M, Hasegawa M, Takio K, Suzuki M, Yoshida H, Titani K, et al. Proline-directed and non-proline-directed phosphorylation of PHF-tau. J Biol Chem (1995) 270:823-9. doi:10.1074/jbc.270.2.823
16. Hanger DP, Betts JC, Loviny TL, Blackstock WP, Anderton BH. New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry. J Neurochem (1998) 71:2465-76. doi:10.1046/j.1471-4159.1998.71062465.x
17. Tavares IA, Touma D, Lynham S, Troakes C, Schober M, Causevic M, et al. Prostate-derived Sterile 20-like Kinases (PSKs/TAOKs) Phosphorylate Tau Protein and Are Activated in Tangle-bearing Neurons in Alzheimer Disease. J Biol Chem (2013) 288(21):15418-29. doi:10.1074/jbc.M112.448183
18. Hanger DP, Hughes K, Woodgett JR, Brion JP, Anderton BH. Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci Lett (1992) 147:58-62. doi:10.1016/0304-3940(92)90774-2
19. Lovestone S, Reynolds CH, Latimer D, Davis DR, Anderton BH, Gallo JM, et al. Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr Biol (1994) 4:1077-86. doi:10.1016/S0960-9822(00)00246-3
20. Lovestone S, Hartley CL, Pearce J, Anderton BH. Phosphorylation of tau by glycogen synthase kinase-3 beta in intact mammalian cells: the effects on the organization and stability of microtubules. Neuroscience (1996) 73:1145-57. doi:10.1016/0306-4522(96)00126-1
21. Mudher A, Shepherd D, Newman TA, Mildren P, Jukes JP, Squire A, et al. GSK-3beta inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila. Mol Psychiatry (2004) 9:522-30. doi:10.1038/sj.mp.4001483
22. Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F, et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci U S A (2005) 102(19):6990-5. doi:10.1073/pnas.0500466102
23. Baumann K, Mandelkow EM, Biernat J, Piwnica-Worms H, Mandelkow E. Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5. FEBS Lett (1993) 336:417-24. doi:10.1016/0014-5793(93)80849-P
24. Cruz JC, Tseng HC, Goldman JA, Shih H, Tsai LH. Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron (2003) 40:471-83. doi:10.1016/S0896-6273(03)00627-5
25. Noble W, Olm V, Takata K, Casey E, Mary O, Meyerson J, et al. Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron (2003) 38:555-65. doi:10.1016/S0896-6273(03)00259-9
26. Thornton C, Bright NJ, Sastre M, Muckett PJ, Carling D. AMP-activated protein kinase (AMPK) is a tau kinase, activated in response to amyloid beta-peptide exposure. Biochem J (2011) 434:503-12. doi:10.1042/BJ20101485
27. Mairet-Coello G, Courchet J, Pieraut S, Courchet V, Maximov A, Polleux F. The CAMKK2-AMPK kinase pathway mediates the synaptotoxic effects of Abeta oligomers through tau phosphorylation. Neuron (2013) 78:94-108. doi:10.1016/j.neuron.2013.02.003
28. Lee S, Wang JW, Yu W, Lu B. Phospho-dependent ubiquitination and degradation of PAR-1 regulates synaptic morphology and tau-mediated Abeta toxicity in Drosophila. Nat Commun (2012) 3:1312. doi:10.1038/ncomms2278
29. Drewes G, Trinczek B, Illenberger S, Biernat J, Schmitt-Ulms G, Meyer HE, et al. Microtubule-associated protein/microtubule affinity-regulating kinase (p110mark). A novel protein kinase that regulates tau-microtubule interactions and dynamic instability by phosphorylation at the Alzheimer-specific site serine 262. J Biol Chem (1995) 270:7679-88.
30. Trinczek B, Biernat J, Baumann K, Mandelkow EM, Mandelkow E. Domains of tau protein, differential phosphorylation, and dynamic instability of microtubules. Mol Biol Cell (1995) 6:1887-902.
31. Andorfer CA, Davies P. PKA phosphorylations on tau: developmental studies in the mouse. Dev Neurosci (2000) 22:303-9. doi:10.1159/000017454
32. Wang D, Fu Q, Zhou Y, Xu B, Shi Q, Igwe B, et al. Beta2 adrenergic receptor, protein kinase A (PKA) and c-Jun N-terminal kinase (JNK) signaling pathways mediate tau pathology in Alzheimer disease models. J Biol Chem (2013) 288:10298-307. doi:10.1074/jbc.M112.415141
33. Sheppard O, Plattner F, Rubin A, Slender A, Linehan JM, Brandner S, et al. Altered regulation of tau phosphorylation in a mouse model of down syndrome aging. Neurobiol Aging (2012) 33(828):e831-44. doi:10.1016/j.neurobiolaging.2011.06.025
34. Woods YL, Cohen P, Becker W, Jakes R, Goedert M, Wang X, et al. The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bepsilon at Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase. Biochem J (2001) 355:609-15.
35. Williamson R, Scales T, Clark BR, Gibb G, Reynolds CH, Kellie S, et al. Rapid tyrosine phosphorylation of neuronal proteins including tau and focal adhesion kinase in response to amyloid-beta peptide exposure: involvement of Src family protein kinases. J Neurosci (2002) 22:10-20.
36. Lee G, Thangavel R, Sharma VM, Litersky JM, Bhaskar K, Fang SM, et al. Phosphorylation of tau by fyn: implications for Alzheimer's disease. J Neurosci (2004) 24:2304-12. doi:10.1523/JNEUROSCI.4162-03.2004
37. Cancino GI, Perez de Arce K, Castro PU, Toledo EM, Von Bernhardi R, Alvarez AR. c-Abl tyrosine kinase modulates tau pathology and Cdk5 phosphorylation in AD transgenic mice. Neurobiol Aging (2011) 32:1249-61. doi:10.1016/j.neurobiolaging.2009.07.007
38. Derkinderen P, Scales TM, Hanger DP, Leung KY, Byers HL, Ward MA, et al. Tyrosine 394 is phosphorylated in Alzheimer's paired helical filament tau and in fetal tau with c-Abl as the candidate tyrosine kinase. J Neurosci (2005) 25:6584-93. doi:10.1523/JNEUROSCI.1487-05.2005
39. Lebouvier T, Scales TM, Hanger DP, Geahlen RL, Lardeux B, Reynolds CH, et al. The microtubule-associated protein tau is phosphorylated by Syk. Biochim Biophys Acta (2008) 1783:188-92. doi:10.1016/j.bbamcr.2007.11.005
40. Liu F, Grundke-Iqbal I, Iqbal K, Gong CX. Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur J Neurosci (2005) 22:1942-50. doi:10.1111/j.1460-9568.2005.04391.x
41. Williamson R, Usardi A, Hanger DP, Anderton BH. Membrane-bound beta-amyloid oligomers are recruited into lipid rafts by a fyn-dependent mechanism. FASEB J (2008) 22:1552-9. doi:10.1096/fj.07-9766com
42. Killick R, Ribe EM, Al-Shawi R, Malik B, Hooper C, Fernandes C, et al. Clusterin regulates beta-amyloid toxicity via Dickkopf-1-driven induction of the wnt-PCP-JNK pathway. Mol Psychiatry (2012). doi:10.1038/mp.2012.163. [Epub ahead of print].
43. Yoon SO, Park DJ, Ryu JC, Ozer HG, Tep C, Shin YJ, et al. JNK3 perpetuates metabolic stress induced by Abeta peptides. Neuron (2012) 75:824-37. doi:10.1016/j.neuron.2012.06.024
44. Steinhilb ML, Dias-Santagata D, Fulga TA, Felch DL, Feany MB. Tau phosphorylation sites work in concert to promote neurotoxicity in vivo. Mol Biol Cell (2007) 18(12):5060-8. doi:10.1091/mbc.E07-04-0327
45. Yuzwa SA, Yadav AK, Skorobogatko Y, Clark T, Vosseller K, Vocadlo DJ. Mapping O-GlcNAc modification sites on tau and generation of a site-specific O-GlcNAc tau antibody. Amino Acids (2011) 40:857-68. doi:10.1007/s00726-010-0705-1
46. Martin L, Latypova X, Terro F. Post-translational modifications of tau protein: implications for Alzheimer's disease. Neurochem Int (2011) 58:458-71. doi:10.1016/j.neuint.2010.12.023
47. Rissman RA, Poon WW, Blurton-Jones M, Oddo S, Torp R, Vitek MP, et al. Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Invest (2004) 114:121-30. doi:10.1172/JCI20640
48. Park SY, Ferreira A. The generation of a 17 kDa neurotoxic fragment: an alternative mechanism by which tau mediates beta-amyloid-induced neurodegeneration. J Neurosci (2005) 25:5365-75. doi:10.1523/JNEUROSCI.1125-05.2005
49. Horowitz PM, Patterson KR, Guillozet-Bongaarts AL, Reynolds MR, Carroll CA, Weintraub ST, et al. Early N-terminal changes and caspase-6 cleavage of tau in Alzheimer's disease. J Neurosci (2004) 24:7895-902. doi:10.1523/JNEUROSCI.1988-04.2004
50. Ferreira A, Bigio EH. Calpain-mediated tau cleavage: a mechanism leading to neurodegeneration shared by multiple tauopathies. Mol Med (2011) 17:676-85. doi:10.2119/molmed.2010.00220
51. Binder LI, Guillozet-Bongaarts AL, Garcia-Sierra F, Berry RW. Tau, and tangles, Alzheimer's disease. Biochim Biophys Acta (2005) 1739:216-23. doi:10.1016/j.bbadis.2004.08.014
52. Rametti A, Esclaire F, Yardin C, Terro F. Linking alterations in tau phosphorylation and cleavage during neuronal apoptosis. J Biol Chem (2004) 279:54518-28. doi:10.1074/jbc.M408186200
53. Guillozet-Bongaarts AL, Cahill ME, Cryns VL, Reynolds MR, Berry RW, Binder LI. Pseudophosphorylation of tau at serine 422 inhibits caspase cleavage: in vitro evidence and implications for tangle formation in vivo. J Neurochem (2006) 97:1005-14. doi:10.1111/j.1471-4159.2006.03784.x
54. Garwood CJ, Pooler AM, Atherton J, Hanger DP, Noble W. Astrocytes are important mediators of Abeta-induced neurotoxicity and tau phosphorylation in primary culture. Cell Death Dis (2011) 2:e167. doi:10.1038/cddis.2011.50
55. Cho JH, Johnson GV. Glycogen synthase kinase 3 beta induces caspase-cleaved tau aggregation in situ. J Biol Chem (2004) 279:54716-23. doi:10.1074/jbc.M403364200
56. Guillozet-Bongaarts AL, Garcia-Sierra F, Reynolds MR, Horowitz PM, Fu Y, Wang T, et al. Tau truncation during neurofibrillary tangle evolution in Alzheimer's disease. Neurobiol Aging (2005) 26:1015-22. doi:10.1016/j.neurobiolaging.2004.09.019
57. Terwel D, Lasrado R, Snauwaert J, Vandeweert E, Van Haesendonck C, Borghgraef P, et al. Changed conformation of mutant tau-P301L underlies the moribund tauopathy, absent in progressive, nonlethal axonopathy of tau-4R/2N transgenic mice. J Biol Chem (2005) 280(5):3963-73. doi:10.1074/jbc.M409876200
58. Kelleher I, Garwood C, Hanger DP, Anderton BH, Noble W. Kinase activities increase during the development of tauopathy in htau mice. J Neurochem (2007) 103:2256-67. doi:10.1111/j.1471-4159.2007.04930.x
59. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Sarmiento J, Troncoso J, Jackson GR, et al. Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. FASEB J (2012) 26:1946-59. doi:10.1096/fj.11-199851
60. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Clos AL, Jackson GR, Kayed R. Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice. Mol Neurodegener (2011) 6:39. doi:10.1186/1750-1326-6-39
61. Ali YO, Ruan K, Zhai RG. NMNAT suppresses tau-induced neurodegeneration by promoting clearance of hyperphosphorylated tau oligomers in a Drosophila model of tauopathy. Hum Mol Genet (2012) 21:237-50. doi:10.1093/hmg/ddr449
62. Chun W, Johnson GV. The role of tau phosphorylation and cleavage in neuronal cell death. Front Biosci (2007) 12:733-56. doi:10.2741/2097
63. Nubling G, Bader B, Levin J, Hildebrandt J, Kretzschmar H, Giese A. Synergistic influence of phosphorylation and metal ions on tau oligomer formation and coaggregation with alpha-synuclein at the single molecule level. Mol Neurodegener (2012) 7:35. doi:10.1186/1750-1326-7-35
64. Gamblin TC, Chen F, Zambrano A, Abraha A, Lagalwar S, Guillozet AL, et al. Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc Natl Acad Sci U S A (2003) 100(17):10032-7. doi:10.1073/pnas.1630428100
65. Henkins KM, Sokolow S, Miller CA, Vinters HV, Poon WW, Cornwell LB, et al. Extensive p-tau pathology and SDS-stable p-tau oligomers in Alzheimer's cortical synapses. Brain Pathol (2012) 22:826-33. doi:10.1111/j.1750-3639.2012.00598.x
66. Mandelkow EM, Mandelkow E. Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb Perspect Med (2012) 2:a006247. doi:10.1101/cshperspect.a006247
67. Lee G,Leugers CJ. Tau and tauopathies. Prog Mol Biol Transl Sci (2012) 107:263-93. doi:10.1016/B978-0-12-385883-2.00004-7
68. Alonso A, Zaidi T, Novak M, Grundke-Iqbal I, Iqbal K. Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc Natl Acad Sci U S A (2001) 98(12):6923-8. doi:10.1073/pnas.121119298
69. Chohan MO, Haque N, Alonso A, El-Akkad E, Grundke-Iqbal I, Grover A, et al. Hyperphosphorylation-induced self assembly of murine tau: a comparison with human tau. J Neural Transm (2005) 112:1035-47. doi:10.1007/s00702-004-0241-9
70. Iqbal K, Alonso AC, Gong CX, Khatoon S, Pei JJ, Wang JZ, et al. Mechanisms of neurofibrillary degeneration and the formation of neurofibrillary tangles. J Neural Transm Suppl (1998) 53:169-80. doi:10.1007/978-3-7091-6467-9_15
71. Lucas JJ, Hernandez F, Gomez-Ramos P, Moran MA, Hen R, Avila J. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J (2001) 20:27-39. doi:10.1093/emboj/20.1.27
72. Le Corre S, Klafki HW, Plesnila N, Hubinger G, Obermeier A, Sahagun H, et al. An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proc Natl Acad Sci U S A (2006) 103:9673-8. doi:10.1073/pnas.0602913103
73. Sundaram JR, Poore CP, Sulaimee NH, Pareek T, Asad AB, Rajkumar R, et al. Specific inhibition of p25/Cdk5 activity by the Cdk5 inhibitory peptide reduces neurodegeneration in vivo. J Neurosci (2013) 33:334-43. doi:10.1523/JNEUROSCI.3593-12.2013
74. Shimada K, Motoi Y, Ishiguro K, Kambe T, Matsumoto SE, Itaya M, et al. Long-term oral lithium treatment attenuates motor disturbance in tauopathy model mice: implications of autophagy promotion. Neurobiol Dis (2012) 46:101-8. doi:10.1016/j.nbd.2011.12.050
75. Schneider A, Biernat J, Von Bergen M, Mandelkow E, Mandelkow EM. Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry (1999) 38:3549-58. doi:10.1021/bi981874p
76. Kins S, Kurosinski P, Nitsch RM, Götz J. Activation of the ERK and JNK signaling pathways caused by neuron-specific inhibition of PP2A in transgenic mice. Am J Pathol (2003) 163(3):833-43. doi:10.1016/S0002-9440(10)63444-X
77. Louis JV, Martens E, Borghgraef P, Lambrecht C, Sents W, Longin S, et al. Mice lacking phosphatase PP2A subunit PR61/B'delta (Ppp2r5d) develop spatially restricted tauopathy by deregulation of CDK5 and GSK3beta. Proc Natl Acad Sci U S A (2011) 108(17):6957-62. doi:10.1073/pnas.1018777108
78. Götz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science (2001) 293(5534):1491-5. doi:10.1126/science.1062097
79. de Calignon A, Fox LM, Pitstick R, Carlson GA, Bacskai BJ, Spires-Jones TL, et al. Caspase activation precedes and leads to tangles. Nature (2010) 464(7292):1201-4. doi:10.1038/nature08890
80. Congdon EE, Duff KE. Is tau aggregation toxic or protective?. J Alzheimers Dis (2008) 14:453-7.
81. Kanai Y, Hirokawa N. Sorting mechanisms of tau and MAP2 in neurons: suppressed axonal transit of MAP2 and locally regulated microtubule binding. Neuron (1995) 14:421-32. doi:10.1016/0896-6273(95)90298-8
82. Aronov S, Aranda G, Behar L, Ginzburg I. Visualization of translated tau protein in the axons of neuronal P19 cells and characterization of tau RNP granules. J Cell Sci (2002) 115:3817-27. doi:10.1242/jcs.00058
83. Li X, Kumar Y, Zempel H, Mandelkow EM, Biernat J, Mandelkow E. Novel diffusion barrier for axonal retention of tau in neurons and its failure in neurodegeneration. EMBO J (2011) 30:4825-37. doi:10.1038/emboj.2011.376
84. Morita T, Sobue K. Specification of neuronal polarity regulated by local translation of CRMP2 and tau via the mTOR-p70S6K pathway. J Biol Chem (2009) 284:27734-45. doi:10.1074/jbc.M109.008177
85. Hirokawa N, Funakoshi T, Sato-Harada R, Kanai Y. Selective stabilization of tau in axons and microtubule-associated protein 2C in cell bodies and dendrites contributes to polarized localization of cytoskeletal proteins in mature neurons. J Cell Biol (1996) 132:667-79. doi:10.1083/jcb.132.4.667
86. Andorfer C, Kress Y, Espinoza M, de Silva R, Tucker KL, Barde YA, et al. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem (2003) 86:582-90. doi:10.1046/j.1471-4159.2003.01879.x
87. Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol (2011) 70:960-9. doi:10.1097/NEN.0b013e318232a379
88. Cho JH, Johnson GV. Glycogen synthase kinase 3beta phosphorylates tau at both primed and unprimed sites. Differential impact on microtubule binding. J Biol Chem (2003) 278:187-93. doi:10.1074/jbc.M206236200
89. Lu PJ, Wulf G, Zhou XZ, Davies P, Lu KP. The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature (1999) 399:784-8. doi:10.1038/21650
90. Zhou XZ, Kops O, Werner A, Lu PJ, Shen M, Stoller G, et al. Pin1-dependent prolyl isomerization regulates dephosphorylation of Cdc25C and tau proteins. Mol Cell (2000) 6(4):873-83. doi:10.1016/S1097-2765(05)00083-3
91. Landrieu I, Smet-Nocca C, Amniai L, Louis JV, Wieruszeski JM, Goris J, et al. Molecular implication of PP2A and Pin1 in the Alzheimer's disease specific hyperphosphorylation of Tau. PLoS One (2011) 6(6):e21521. doi:10.1371/journal.pone.0021521
92. Alonso AC, Grundke-Iqbal I, Iqbal K. Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat Med (1996) 2:783-7. doi:10.1038/nm0796-783
93. Alonso Adel C, Li B, Grundke-Iqbal I, Iqbal K. Polymerization of hyperphosphorylated tau into filaments eliminates its inhibitory activity. Proc Natl Acad Sci U S A (2006) 103(23):8864-9. doi:10.1073/pnas.0603214103
94. Brunden KR, Ballatore C, Lee VM, Smith AB III, Trojanowski JQ. Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies. Biochem Soc Trans (2012) 40:661-6. doi:10.1042/BST20120010
95. Zhang B, Carroll J, Trojanowski JQ, Yao Y, Iba M, Potuzak JS, et al. The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J Neurosci (2012) 32:3601-11. doi:10.1523/JNEUROSCI.4922-11.2012
96. Utton MA, Noble WJ, Hill JE, Anderton BH, Hanger DP. Molecular motors implicated in the axonal transport of tau and alpha-synuclein. J Cell Sci (2005) 118:4645-54. doi:10.1242/jcs.02558
97. Cuchillo-Ibanez I, Seereeram A, Byers HL, Leung KY, Ward MA, Anderton BH, et al. Phosphorylation of tau regulates its axonal transport by controlling its binding to kinesin. FASEB J (2008) 22:3186-95. doi:10.1096/fj.08-109181
98. Rodríguez-Martín T, Cuchillo-Ibáñez I, Noble W, Nyenya F, Anderton BH, Hanger DP. Tau phosphorylation affects its axonal transport and degradation. Neurobiol Aging (2013) 34(9):2146-57. doi:10.1016/j.neurobiolaging.2013.03.015
99. Dixit R, Ross JL, Goldman YE, Holzbaur EL. Differential regulation of dynein and kinesin motor proteins by tau. Science (2008) 319:1086-9. doi:10.1126/science.1152993
100. Kanaan NM, Morfini G, Pigino G, Lapointe NE, Andreadis A, Song Y, et al. Phosphorylation in the amino terminus of tau prevents inhibition of anterograde axonal transport. Neurobiol Aging (2012) 33(826):e815-30. doi:10.1016/j.neurobiolaging.2011.06.006
101. Ittner LM, Fath T, Ke YD, Bi M, van Eersel J, Li KM, et al. Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia. Proc Natl Acad Sci U S A (2008) 105:15997-6002. doi:10.1073/pnas.0808084105
102. Ittner LM, Ke YD, Gotz J. Phosphorylated tau interacts with c-Jun N-terminal kinase-interacting protein 1 (JIP1) in Alzheimer disease. J Biol Chem (2009) 284:20909-16. doi:10.1074/jbc.M109.014472
103. Mandelkow EM, Stamer K, Vogel R, Thies E, Mandelkow E. Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol Aging (2003) 24:1079-85. doi:10.1016/j.neurobiolaging.2003.04.007
104. De Vos KJ, Grierson AJ, Ackerley S, Miller CC. Role of axonal transport in neurodegenerative diseases. Annu Rev Neurosci (2008) 31:151-73. doi:10.1146/annurev.neuro.31.061307.090711
105. Iijima-Ando K, Sekiya M, Maruko-Otake A, Ohtake Y, Suzuki E, Lu B, et al. Loss of axonal mitochondria promotes tau-mediated neurodegeneration and Alzheimer's disease-related tau phosphorylation via PAR-1. PLoS Genet (2012) 8:e1002918. doi:10.1371/journal.pgen.1002918
106. Falzone TL, Gunawardena S, McCleary D, Reis GF, Goldstein LS. Kinesin-1 transport reductions enhance human tau hyperphosphorylation, aggregation and neurodegeneration in animal models of tauopathies. Hum Mol Genet (2010) 19:4399-408. doi:10.1093/hmg/ddq363
107. Martin LJ. Biology of mitochondria in neurodegenerative diseases. Prog Mol Biol Transl Sci (2012) 107:355-415. doi:10.1016/B978-0-12-385883-2.00005-9
108. Kopeikina KJ, Carlson GA, Pitstick R, Ludvigson AE, Peters A, Luebke JI, et al. Tau accumulation causes mitochondrial distribution deficits in neurons in a mouse model of tauopathy and in human Alzheimer's disease brain. Am J Pathol (2011) 179:2071-82. doi:10.1016/j.ajpath.2011.07.004
109. Ebneth A, Godemann R, Stamer K, Illenberger S, Trinczek B, Mandelkow E. Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer's disease. J Cell Biol (1998) 143:777-94. doi:10.1083/jcb.143.3.777
110. Shahpasand K, Uemura I, Saito T, Asano T, Hata K, Shibata K, et al. Regulation of mitochondrial transport and inter-microtubule spacing by tau phosphorylation at the sites hyperphosphorylated in Alzheimer's disease. J Neurosci (2012) 32:2430-41. doi:10.1523/JNEUROSCI.5927-11.2012
111. Manczak M, Reddy PH. Abnormal interaction between the mitochondrial fission protein Drp1 and hyperphosphorylated tau in Alzheimer's disease neurons: implications for mitochondrial dysfunction and neuronal damage. Hum Mol Genet (2012) 21:2538-47. doi:10.1093/hmg/dds072
112. DuBoff B, Götz J, Feany MB. Tau promotes neurodegeneration via DRP1 mislocalization in vivo. Neuron (2012) 75(4):618-32. doi:10.1016/j.neuron.2012.06.026
113. DuBoff B, Feany M, Gotz J. Why size matters - balancing mitochondrial dynamics in Alzheimer's disease. Trends Neurosci (2013). doi:10.1016/j.tins.2013.03.002
114. Farah CA, Perreault S, Liazoghli D, Desjardins M, Anton A, Lauzon M, et al. Tau interacts with Golgi membranes and mediates their association with microtubules. Cell Motil Cytoskeleton (2006) 63:710-24. doi:10.1002/cm.20157
115. Brandt R, Leger J, Lee G. Interaction of tau with the neural plasma membrane mediated by tau's amino-terminal projection domain. J Cell Biol (1995) 131:1327-40. doi:10.1083/jcb.131.5.1327
116. Pooler AM, Usardi A, Evans CJ, Philpott KL, Noble W, Hanger DP. Dynamic association of tau with neuronal membranes is regulated by phosphorylation. Neurobiol Aging (2012) 33(431):e427-38. doi:10.1016/j.neurobiolaging.2011.01.005
117. Maas T, Eidenmuller J, Brandt R. Interaction of tau with the neural membrane cortex is regulated by phosphorylation at sites that are modified in paired helical filaments. J Biol Chem (2000) 275:15733-40. doi:10.1074/jbc.M000389200
118. Pooler AM, Hanger DP. Functional implications of the association of tau with the plasma membrane. Biochem Soc Trans (2010) 38:1012-5. doi:10.1042/BST0381012
119. Arrasate M, Perez M, Avila J. Tau dephosphorylation at tau-1 site correlates with its association to cell membrane. Neurochem Res (2000) 25:43-50. doi:10.1023/A:1007583214722
120. Ekinci FJ, Shea TB. Phosphorylation of tau alters its association with the plasma membrane. Cell Mol Neurobiol (2000) 20:497-508. doi:10.1023/A:1007075115574
121. Usardi A, Pooler AM, Seereeram A, Reynolds CH, Derkinderen P, Anderton B, et al. Tyrosine phosphorylation of tau regulates its interactions with Fyn SH2 domains, but not SH3 domains, altering the cellular localization of tau. FEBS J (2011) 278:2927-37. doi:10.1111/j.1742-4658
122. Reynolds CH, Garwood CJ, Wray S, Price C, Kellie S, Perera T, et al. Phosphorylation regulates tau interactions with Src homology 3 domains of phosphatidylinositol 3-kinase, phospholipase Cgamma1, Grb2, and Src family kinases. J Biol Chem (2008) 283:18177-86. doi:10.1074/jbc.M709715200
123. Hall GF, Lee VM, Lee G, Yao J. Staging of neurofibrillary degeneration caused by human tau overexpression in a unique cellular model of human tauopathy. Am J Pathol (2001) 158:235-46. doi:10.1016/S0002-9440(10)63962-4
124. Katsuse O, Lin WL, Lewis J, Hutton ML, Dickson DW. Neurofibrillary tangle-related synaptic alterations of spinal motor neurons of P301L tau transgenic mice. Neurosci Lett (2006) 409:95-9. doi:10.1016/j.neulet.2006.09.021
125. Eckermann K, Mocanu MM, Khlistunova I, Biernat J, Nissen A, Hofmann A, et al. The beta-propensity of tau determines aggregation and synaptic loss in inducible mouse models of tauopathy. J Biol Chem (2007) 282:31755-65. doi:10.1074/jbc.M705282200
126. Tai HC, Serrano-Pozo A, Hashimoto T, Frosch MP, Spires-Jones TL, Hyman BT. The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. Am J Pathol (2012) 181:1426-35. doi:10.1016/j.ajpath.2012.06.033
127. Zempel H, Thies E, Mandelkow E, Mandelkow EM. Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. J Neurosci (2010) 30:11938-50. doi:10.1523/JNEUROSCI.2357-10.2010
128. Zempel H, Mandelkow EM. Linking amyloid-beta and tau: amyloid-beta induced synaptic dysfunction via local wreckage of the neuronal cytoskeleton. Neurodegener Dis (2012) 10:64-72. doi:10.1159/000332816
129. Hoover BR, Reed MN, Su J, Penrod RD, Kotilinek LA, Grant MK, et al. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron (2010) 68:1067-81. doi:10.1016/j.neuron.2010.11.030
130. Crimins JL, Pooler A, Polydoro M, Luebke JI, Spires-Jones TL. The intersection of amyloid beta and tau in glutamatergic synaptic dysfunction and collapse in Alzheimer's disease. Ageing Res Rev (2013) doi:10.1016/j.arr.2013.03.002. [Epub ahead of print].
131. Hooper C, Markevich V, Plattner F, Killick R, Schofield E, Engel T, et al. Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. Eur J Neurosci (2007) 25:81-6. doi:10.1111/j.1460-9568.2006.05245.x
132. Loomis PA, Howard TH, Castleberry RP, Binder LI. Identification of nuclear tau isoforms in human neuroblastoma cells. Proc Natl Acad Sci U S A (1990) 87:8422-6. doi:10.1073/pnas.87.21.8422
133. Qu MH, Li H, Tian R, Nie CL, Liu Y, Han BS, et al. Neuronal tau induces DNA conformational changes observed by atomic force microscopy. Neuroreport (2004) 15:2723-7.
134. Kampers T, Friedhoff P, Biernat J, Mandelkow EM, Mandelkow E. RNA stimulates aggregation of microtubule-associated protein tau into Alzheimer-like paired helical filaments. FEBS Lett (1996) 399:344-9. doi:10.1016/S0014-5793(96)01386-5
135. Krylova SM, Musheev M, Nutiu R, Li Y, Lee G, Krylov SN. Tau protein binds single-stranded DNA sequence specifically - the proof obtained in vitro with non-equilibrium capillary electrophoresis of equilibrium mixtures. FEBS Lett (2005) 579:1371-5. doi:10.1016/j.febslet.2005.01.032
136. Li W, Wang XS, Qu MH, Liu Y, He RQ. Human protein tau represses DNA replication in vitro. Biochim Biophys Acta (2005) 1726:280-6. doi:10.1016/j.bbagen.2005.08.014
137. Sultan A, Nesslany F, Violet M, Begard S, Loyens A, Talahari S, et al. Nuclear tau, a key player in neuronal DNA protection. J Biol Chem (2011) 286:4566-75. doi:10.1074/jbc.M110.199976
138. Yamada K, Cirrito JR, Stewart FR, Jiang H, Finn MB, Holmes BB, et al. In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J Neurosci (2011) 31(37):13110-7. doi:10.1523/JNEUROSCI.2569-11.2011
139. de Calignon A, Polydoro M, Suarez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, et al. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron (2012) 73:685-97. doi:10.1016/j.neuron.2011.11.033
140. Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, et al. Trans-synaptic spread of tau pathology in vivo. PLoS One (2012) 7:e31302. doi:10.1371/journal.pone.0031302
141. Frost B, Jacks RL, Diamond MI. Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem (2009) 284:12845-52. doi:10.1074/jbc.M808759200
142. Wu JW, Herman M, Liu L, Simoes S, Acker CM, Figueroa H, et al. Small misfolded tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons. J Biol Chem (2013) 288:1856-70. doi:10.1074/jbc.M112.394528
143. Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol (2009) 11:909-13. doi:10.1038/ncb1901
144. Clavaguera F, Lavenir I, Falcon B, Frank S, Goedert M, Tolnay M. "Prion-like" templated misfolding in tauopathies. Brain Pathol (2013) 23:342-9. doi:10.1111/bpa.12044
145. Chai X, Dage JL, Citron M. Constitutive secretion of tau protein by an unconventional mechanism. Neurobiol Dis (2012) 48:356-66. doi:10.1016/j.nbd.2012.05.021
146. Pooler AM, Phillips EC, Lau DH, Noble W, Hanger DP. Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep (2013) 14:389-94. doi:10.1038/embor.2013.15
147. Gomez-Ramos A, Diaz-Hernandez M, Rubio A, Miras-Portugal MT, Avila J. Extracellular tau promotes intracellular calcium increase through M1 and M3 muscarinic receptors in neuronal cells. Mol Cell Neurosci (2008) 37:673-81. doi:10.1016/j.mcn.2007.12.010
148. Gorlovoy P, Larionov S, Pham TT, Neumann H. Accumulation of tau induced in neurites by microglial proinflammatory mediators. FASEB J (2009) 23:2502-13. doi:10.1096/fj.08-123877
149. Diaz-Hernandez M, Gomez-Ramos A, Rubio A, Gomez-Villafuertes R, Naranjo JR, Miras-Portugal MT, et al. Tissue-nonspecific alkaline phosphatase promotes the neurotoxicity effect of extracellular tau. J Biol Chem (2010) 285:32539-48. doi:10.1074/jbc.M110.145003
150. Plouffe V, Mohamed NV, Rivest-McGraw J, Bertrand J, Lauzon M, Leclerc N. Hyperphosphorylation and cleavage at D421 enhance tau secretion. PLoS One (2012) 7:e36873. doi:10.1371/journal.pone.0036873
151. Yoshiyama Y, Lee VM, Trojanowski JQ. Therapeutic strategies for tau mediated neurodegeneration. J Neurol Neurosurg Psychiatry (2013) 84(7):784-95. doi:10.1136/jnnp-2012-303144
152. Caccamo A, Oddo S, Tran LX, Laferla FM. Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles. Am J Pathol (2007) 170:1669-75. doi:10.2353/ajpath.2007.061178
153. Macdonald A, Briggs K, Poppe M, Higgins A, Velayudhan L, Lovestone S. A feasibility and tolerability study of lithium in Alzheimer's disease. Int J Geriatr Psychiatry (2008) 23:704-11. doi:10.1002/gps.1964
154. Hampel H, Ewers M, Burger K, Annas P, Mortberg A, Bogstedt A, et al. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry (2009) 70:922-31. doi:10.4088/JCP.08m04606
155. Forlenza OV, Diniz BS, Radanovic M, Santos FS, Talib LL, Gattaz WF. Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry (2011) 198:351-6. doi:10.1192/bjp.bp.110.080044
156. Sereno L, Coma M, Rodriguez M, Sanchez-Ferrer P, Sanchez MB, Gich I, et al. A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo. Neurobiol Dis (2009) 35:359-67. doi:10.1016/j.nbd.2009.05.025
157. Del Ser T, Steinwachs KC, Gertz HJ, Andres MV, Gomez-Carrillo B, Medina M, et al. Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study. J Alzheimers Dis (2013) 33:205-15. doi:10.3233/JAD-2012-120805
158. D'Cruz OJ, Uckun FM. Protein kinase inhibitors against malignant lymphoma. Expert Opin Pharmacother (2013) 14:707-21. doi:10.1517/14656566.2013.780031
159. Wang H, Brautigan DL. A novel transmembrane Ser/Thr kinase complexes with protein phosphatase-1 and inhibitor-2. J Biol Chem (2002) 277:49605-12. doi:10.1074/jbc.M209335200
160. Manser C, Guillot F, Vagnoni A, Davies J, Lau KF, McLoughlin DM, et al. Lemur tyrosine kinase-2 signalling regulates kinesin-1 light chain-2 phosphorylation and binding of Smad2 cargo. Oncogene (2012) 31:2773-82. doi:10.1038/onc.2011.437
161. Manser C, Vagnoni A, Guillot F, Davies J, Miller CC. Cdk5/p35 phosphorylates lemur tyrosine kinase-2 to regulate protein phosphatase-1C phosphorylation and activity. J Neurochem (2012) 121:343-8. doi:10.1111/j.1471-4159.2012.07650.x
162. Morfini G, Szebenyi G, Brown H, Pant HC, Pigino G, Deboer S, et al. A novel CDK5-dependent pathway for regulating GSK3 activity and kinesin-driven motility in neurons. EMBO J (2004) 23:2235-45. doi:10.1038/sj.emboj.7600237
163. Hernandez F, Langa E, Cuadros R, Avila J, Villanueva N. Regulation of GSK3 isoforms by phosphatases PP1 and PP2A. Mol Cell Biochem (2010) 344:211-5. doi:10.1007/s11010-010-0544-0
164. Dar AC, Shokat KM. The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling. Annu Rev Biochem (2011) 80:769-95. doi:10.1146/annurev-biochem-090308-173656
165. Lovestone S. Searching for biomarkers in neurodegeneration. Nat Med (2010) 16:1371-2. doi:10.1038/nm1210-1371b